| Title |
Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma
|
|---|---|
| Published in |
Leukemia, November 2017
|
| DOI | 10.1038/leu.2017.316 |
| Pubmed ID | |
| Authors |
J Bae, T Hideshima, G L Zhang, J Zhou, D B Keskin, N C Munshi, K C Anderson |
| Abstract |
XBP1 (X-box binding protein 1), CD138 (Syndecan-1), and CS1 (SLAMF7) are highly expressed antigens in cancers including multiple myeloma (MM). Here we identify and characterize immunogenic HLA-A24 peptides derived from these antigens for potential vaccination therapy of HLA-A24+ patients with MM. The identified immunogenic HLA-A24-specific XBP1 unspliced (UN)185-193 (I S P W I L A V L), XBP1 spliced (SP)223-231 (V Y P E G P S S L), CD138265-273 (I F A V C L V G F) and CS1240-248 (L F V L G L F L W) peptides induced antigen-specific CTL with anti-MM activity in an HLA-A24 restricted manner. Furthermore, a cocktail containing the four HLA-A24 peptides evoked MM-specific CTL with distinct phenotypic profiles (CD28, CD40L, 41BB, CD38, CD69) and anti-tumor activities, evidenced by perforin upregulation, CD107a degranulation (cytotoxicity) and Th1 type cytokines (IFN-γ/IL-2/TNF-α) production in response to HLA-A24(+) MM cells. The multipeptide-specific CTL included antigen-specific memory CD8(+) T cells expressing both T cell activation (CD38, CD69) and immune checkpoints antigens (CTLA, PD1, LAG3, TIM3). These results provide the framework for a multipeptide vaccination therapy to induce tumor-specific CTL in HLA-A24 positive patients with myeloma and other cancers expressing these antigens.Leukemia accepted article preview online, 01 November 2017. doi:10.1038/leu.2017.316. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 13% |
| Student > Ph. D. Student | 3 | 13% |
| Researcher | 3 | 13% |
| Student > Doctoral Student | 2 | 8% |
| Student > Bachelor | 2 | 8% |
| Other | 5 | 21% |
| Unknown | 6 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 42% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Computer Science | 1 | 4% |
| Agricultural and Biological Sciences | 1 | 4% |
| Immunology and Microbiology | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2023.
All research outputs
#6,467,890
of 24,003,070 outputs
Outputs from Leukemia
#2,103
of 5,213 outputs
Outputs of similar age
#101,601
of 332,871 outputs
Outputs of similar age from Leukemia
#22
of 55 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 5,213 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,871 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.